J Korean Med Sci.  2006 Apr;21(2):188-192. 10.3346/jkms.2006.21.2.188.

Synergy of Arbekacin-based Combinations Against Vancomycin Hetero-intermediate Staphylococcus aureus

• Lee JY
• Oh WS
• Ko KS
• Heo ST
• Moon CS
• Ki HK
• Kiem S
• Peck KR
• Song JH

• KMID: 1781820
• DOI: http://doi.org/10.3346/jkms.2006.21.2.188

Abstract

This study was undertaken to evaluate the in vitro activities of arbekacin-based combination regimens against vancomycin hetero-intermediate Staphylococcus aureus (hetero-VISA). Combinations of arbekacin with vancomycin, rifampin, ampicillin-sulbactam, teicoplanin, or quinipristin-dalfopristin against seven hetero-VISA strains and two methicillin-resistant S. aureus strains were evaluated by the time-kill assay. The combinations of arbekacin with vancomycin, teicoplanin, or ampicillinsulbactam showed the synergistic interaction against hetero-VISA strains. Data suggest that these arbekacin-based combination regimens may be useful candidates for treatment options of hetero-VISA infections.

Keyword

Arbekacin; habekacin; Rifampin; Sultamicillin; Teicoplanin quinipristin-dalfopristin; Vancomycin Resistance; Staphylococcus aureus; hetero-VISA; Time-kill assay

MeSH Terms

Virginiamycin/administration & dosage
Vancomycin/*administration & dosage
Teicoplanin/administration & dosage
Sulbactam/administration & dosage
Staphylococcus aureus/*drug effects/isolation & purification
Staphylococcal Infections/drug therapy/microbiology
Microbial Sensitivity Tests
Methicillin Resistance
Humans
Drug Synergism
Drug Resistance, Bacterial
Dibekacin/administration & dosage/*analogs & derivatives
Anti-Bacterial Agents/*administration & dosage
Ampicillin/administration & dosage
Aminoglycosides/*administration & dosage

Figure

• 

  Fig. 1 Time-kill studies of arbekacin-based combination regimens against a representative strain, Mu3. (A) vancomycin; (B) rifampin; (C) ampicillin-sulbactam; (D) teicoplanin; (E) quinupristin-dalfopristin. The results are represented as means±standard deviations. A, arbekacin; V, vancomycin; R, rifampin; A/S, ampicillin-sulbactam; T, teicoplanin; Q/D, quinupristin-dalfopristin.

Reference

1. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997. 40:135–136.

2. Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol. 2002. 56:657–675.

3. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, Cardo D, Fridkin SK. Vancomycin-Resistant Staphylococcus aureus Investigative Team. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 2003. 348:1342–1347.

4. Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flannagan SE, Kolonay JF, Shetty J, Killgore GE, Tenover FC. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science. 2003. 302:1569–1701.

5. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR Morb Mortal Wkly Rep. 2004. 53:322–323.

6. Ariza J, Pujol M, Cabo J, Pena C, Fernandez N, Linares J, Ayats J, Gudiol F. Vancomycin in surgical infections due to methicillin-resistance Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet. 1999. 353:1587–1588.

7. Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP. Vancomycin resistance Staphylococcus aureus. Lancet. 1998. 351:602.

8. Kim MN, Pai CH, Woo JH, Ryu JS, Hiramatsu K. Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol. 2000. 38:3879–3881.

9. Ploy MC, Grelaud C, Martin C, de Lumely L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet. 1998. 351:1212.

10. Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis. 1999. 29:760–767.

11. Bert F, Clarissou J, Durand F, Delefosse D, Chauvet C, Lefebvre P, Lambert N, Branger C. Prevalence, molecular epidemiology, and clinical significance of heterogeneous glycopeptide-intermediate Staphylococcus aureus in live transplant recipients. J Clin Microbiol. 2003. 41:5147–5152.

12. Moore MR, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother. 2003. 47:1262–1266.

13. Naimi TS, Anderson D, O'Boyle C, Boxrud DJ, Johnson SK, Tenover FC, Lynfield R. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. Clin Infect Dis. 2003. 36:1609–1612.

14. Watanabe T, Ohashi K, Matsui K, Kubota T. Comparative studies of the bactericical, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1997. 39:471–476.

15. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis. 2001. 1:147–155.

16. Kondo S, Iinuma K, Yamamoto H, Maeda K, Umezawa H. Synthesis of 1-N-(S-4-amino-2-hydroxybutyryl)-kanamycin B and 3'-, 4'-dideoxykanamycin B active against kanamycin-resistant bacteria. J Antibiotics. 1973. 26:412–415.

17. Kondo S, Tamura A, Gomi S, Ikeda Y, Takeuchi T, Mitsuhashi S. Structures of enzymatically modified products of arbekacin by meticillin-resistant Staphylococcus aureus. J Antibiotics. 1993. 46:310–315.

18. Osakabe Y, Takahashi Y, Narihara K. The utility and dosage and administration of arbekacin in patients with MRSA infection. Antibiot Chemother. 1996. 12:120–127.

19. Hamilton-Miller MT, Shah S. Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococus aureus. J Antimicrob Chemother. 1995. 35:865–868.

20. You I, Kariyama R, Zervos MJ, Kumon H, Chow JW. In-vitro activity of arbekacin alone and in combination with vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis. 2000. 36:37–41.

21. NCCLS. Performance standards for antimicrobial susceptibility testing; 13th Informational Supplement. 2003. M100-S13.

22. Eliopoulos GM, Moellering RC. Lorian V, editor. Antimicrobial combinations. Antibiotics in Laboratory Medicine. 1996. 4th edn. Baltimore: Williams & Wilkins;330–396.

23. LaPante KL, Rybak MJ. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn Microbiol Infect Dis. 2004. 50:125–130.

24. Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis. 1999. 29:760–767.

25. Tenover FC, Weigel LM, Appelbaum PC, McDougal LK, Chaitram J, McAllister S, Clark N, Killgore G, O'Hara CM, Jevitt L, Patel JB, Bozdogan B. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother. 2004. 48:275–280.

26. Whitener CJ, Park SY, Browne FA, Parent LJ, Julian K, Bozdogan B, Appelbaum PC, Chaitram J, Weigel LM, Jernigan J, McDougal LK, Tenover FC, Fridkin SK. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis. 2004. 38:1049–1055.

27. Hotta K, Zhu CB, Ogata T, Sunada A, Ishikawa J, Mizuno S, Ikeda Y, Kondo S. Enzymatic 2''-N-acetylation of arbekacin and antibiotic activity of its product. J Antibiotics. 1996. 49:458–464.

28. Suzuki K. Efficacy and safety of arbekacin for staphylococcal infection in the NICU. Pediatr Int. 2003. 45:301–306.

29. Akins PL, Rybak MJ. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother. 2000. 44:1925–1929.

30. Lee DG, Chun HS, Yim DS, Choi SM, Choi JH, Yoo JH, Shin WS, Kang MW. Efficacies of vancomycin, arbekacin, and gentamicin alone or in combination against methicillin-resistant Staphylococcus aureus in an in vitro infective endocarditis model. Antimicrob Agents Chemother. 2003. 47:3768–3773.

31. Kumon H, Mizuno A, Nasu Y, Tsugawa M, Kishi M, Ohmori H. Pharmacokinetics of arbekacin in healthy volunteers and patients with renal insufficiency. Jpn J Antibiotics. 1989. 42:200–207.